相关实验视频

Updated: Jan 17, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

沙雷胺在壮病中的长期抗瘤作用

Romy van der Groef^1,2, Sophie Veldhuijzen van Zanten^2,3,4, Denise van Beekveld³

¹Department of Internal Medicine, Section Endocrinology, Erasmus Medical Centre, Rotterdam 3015 GD, The Netherlands.

European journal of endocrinology

|September 20, 2025

概括

长效释放帕西雷 (LAR) 显示,在8年多的时间里,在壮病患者中,它具有持续的抗瘤作用,导致瘤缩和治疗需求减少. 这种体静止素受体连接体显示出对长期垂体瘤管理的前途.

科学领域:

内分泌学在内分泌学.
在瘤学瘤学.
放射学放射学是一门学科.

背景情况:

巨症是一种由多余的生长激素引起的疾病,通常是由于垂体瘤.
长效释放 (LAR),一个体静止素受体连接体,已经显示出在治疗体缩性垂体瘤的潜力.
有限的长期数据存在于沙利胺的抗瘤作用和临床影响.

研究的目的:

为了评估在患有壮病的患者中,沙雷胺LAR的长期抗瘤作用.
评估沙雷胺LAR对8年内临床结果的影响.

主要方法:

追溯队列研究,包括PAPE研究中的患者.
瘤特征,临床结果和药物使用被评估了8年.
分析了T2加权的MRI信号,瘤体积和T2强度比 (IRs).

主要成果:

帕西雷奥提德治疗导致T2-IR显著增加,表明囊性退行 (1.03至1.56,P<.001).
瘤体积显著减少,中位数为1239至603毫米3 (P = .005).
27.3%的患者由于IGF1水平降低而需要更少的医疗壮症治疗,避免手术或放射治疗.

结论:

帕西里奥提德LAR在体瘤中诱导持久的囊性退行.
观察到持续的抗瘤作用,可能超出治疗范围.
帕西里欧提德LAR在壮病管理中可能具有更广泛的治疗作用,需要前性验证.

关键词:

磁力共振成像T2强度亚克罗梅加利症是什么它具有抗瘤作用.囊性退行症囊性退行症沙特化物是什么意思瘤是一个瘤.

更多相关视频

Laparoscopic Posterior Radical Antegrade Modular Pancreatosplenectomy for Distal Pancreatic Carcinoma

Laparoscopic Posterior Radical Antegrade Modular Pancreatosplenectomy for Distal Pancreatic Carcinoma

Published on: December 29, 2023

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...